Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$0.19 - $0.37 $34,270 - $66,736
180,369 Added 1665.76%
191,197 $43,000
Q3 2023

Nov 14, 2023

BUY
$0.37 - $1.04 $4,006 - $11,261
10,828 New
10,828 $4,000
Q1 2023

May 15, 2023

SELL
$0.76 - $1.78 $17,028 - $39,882
-22,406 Reduced 62.78%
13,282 $12,000
Q4 2022

Feb 14, 2023

BUY
$1.0 - $58.8 $21,508 - $1.26 Million
21,508 Added 151.68%
35,688 $51,000
Q3 2022

Nov 14, 2022

BUY
$1.32 - $58.0 $18,717 - $822,440
14,180 New
14,180 $21,000
Q1 2022

May 16, 2022

BUY
$1.82 - $3.5 $33,659 - $64,729
18,494 Added 105.9%
35,958 $81,000
Q4 2021

Feb 14, 2022

SELL
$1.21 - $2.7 $9,454 - $21,097
-7,814 Reduced 30.91%
17,464 $22,000
Q3 2021

Nov 15, 2021

BUY
$2.59 - $3.36 $6,601 - $8,564
2,549 Added 11.21%
25,278 $67,000
Q3 2020

Nov 16, 2020

BUY
$2.9 - $4.29 $406 - $600
140 Added 0.62%
22,729 $76,000
Q2 2020

Aug 14, 2020

SELL
$1.99 - $3.64 $3,792 - $6,937
-1,906 Reduced 7.78%
22,589 $71,000
Q1 2020

May 15, 2020

SELL
$0.28 - $6.23 $1,969 - $43,821
-7,034 Reduced 22.31%
24,495 $59,000
Q2 2019

Aug 14, 2019

BUY
$1.2 - $1.85 $37,834 - $58,328
31,529 New
31,529 $39,000

Others Institutions Holding GNPX

About Genprex, Inc.


  • Ticker GNPX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,020,300
  • Market Cap $39.9M
  • Description
  • Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...
More about GNPX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.